Envudeucitinibum is a highly selective, allosteric, and orally active TYK2 inhibitor that binds to the JH2 domain of TYK2. It exhibits no off-target effects on other kinases (JAK1-3). It reduces signaling and the production of proinflammatory cytokines including IL-12, IL-23, IL-17, and type I interferons (IFNs). It can be utilized for research related to plaque psoriasis, systemic lupus erythematosus (SLE), and other immune-mediated diseases.
- Highly selective, allosteric, and orally active TYK2 inhibitor
- Binds to the JH2 domain of TYK2
- Exhibits no off-target effects on other kinases (JAK1-3)
- Reduces signaling and production of proinflammatory cytokines
- Potentially useful for research on immune-mediated diseases